131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study

References

Page 1

	Year	Citations
Nonparametric Estimation from Incomplete Observations Edward L. Kaplan, Paul Meier Journal of the American Statistical Association EngineeringAgingLife PredictionRare Event EstimationMortality Rates	1958	38.7K
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-<i>cis</i>-Retinoic Acid Katherine K. Matthay, Judith G. Villablanca, Robert C. Seeger, New England Journal of Medicine	1999	1.9K
Carboplatin dosage: prospective evaluation of a simple formula based on renal function. A. Hilary Calvert, David R. Newell, Lindsey Gumbrell, Journal of Clinical Oncology PharmacotherapyPhysiologically-based Pharmacokinetic ModelingPharmacokineticsCarboplatin DosageRenal Function	1989	1.9K
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-<i>cis</i>-Retinoic Acid: A Children's Oncology Group Study Katherine K. Matthay, C. Patrick Reynolds, Robert C. Seeger, Journal of Clinical Oncology	2009	846
Scintigraphic Localization of Pheochromocytoma James C. Sisson, Marc Frager, Timothy W. Valk, New England Journal of Medicine UrologyScintigraphic LocalizationReliable LocalizationHealth SciencesEndocrine Disease	1981	544
Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. Brahm Shapiro, J Copp, James C. Sisson, PubMed Iodine-131 Mibg ScintigraphyHealth SciencesEndocrine DiseaseMedicineSurgical Pathology	1985	351
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial Susan G. Kreissman, Robert C. Seeger, Katherine K. Matthay, The Lancet Oncology	2013	305
Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory Neuroblastoma Katherine K. Matthay, Gregory A. Yanik, Julia A. Messina, Journal of Clinical Oncology	2007	257
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. Katherine K. Matthay, Kenneth B. DeSantes, B.H. Hasegawa, Journal of Clinical Oncology	1998	217

Page 1